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Since the initial efforts to diagnose nonA and nonB
hepatitis (NANBH) based on the exclusion of other
known causes of liver disease, the field has suffered
from a lack of suitable model systems. The transmission
of NANBH to the chimpanzee led to the establishment of
an animal model that contributed to our initial under-
standing of the underlying chronic disease, the physical
properties of the causative agent, and the eventual clon-
ing of hepatitis C virus (HCV) (Alter and Houghton, 2000).
Although it has been over a decade since the cloning of
the viral genome, the development of suitable models
has significantly lagged in comparison to other aspects
of HCV research. However, recently a number of prom-
ising research models have been developed including a
replicon system for analysis of HCV RNA replication, the
use of microarrays to define the transcriptional changes
that occur during acute resolving and chronic infections,
and advances in the evaluation of protective immunity in
chimpanzees. In addition, surrogate systems have been
developed that include transgenic mice expressing HCV
proteins, mice reconstituted with human hepatocytes,
and development of the GBV-B tamarin/hepatocyte cul-
ture model.
HCV: THE INFECTION
The prevalence of HCV infection is 1–2% worldwide
with a number of age, ethnic and geographic hotspots.
Although the overall prevalence of HCV chronicity is 1.8%
in the United States, the most recent National Health and
Nutrition Exam and Survey (NHANES III) (Alter et al.,
1999) indicates that certain groups have an increased
risk. The 30–50 age group has a prevalence of approxi-
1 To whom correspondence and reprint requests should be ad-
dressed at Department of Virology and Immunology, Southwest Foun-1mately 3–4%. The higher prevalence in this group may
correspond to the increase in intravenous drug use
(IVDU) that began in the 1970s.
The virus has a high propensity for causing persistent
infections. Historically, it has been estimated that chronic
infections develop in up to 85% of exposed individuals.
This may be an overestimate based on data from chim-
panzees (Bassett et al., 1998) and recent data in humans
(Vogt et al., 1999; Wiese et al., 2000; Scognamiglio et al.,
1999; Koziel et al., 1997; Barrett et al., 1999). The disease
is typically asymptomatic or mild for several decades;
however, up to 20% of infected individuals will eventually
develop cirrhosis, and some of these cases will progress
to hepatocellular carcinoma (Alter and Seeff, 2000). HCV
infection is the leading cause of liver transplantation in
this country (Conry-Cantilena et al., 1996).
Blood products were a primary means of transmission
prior to the introduction of tests for antibodies to HCV.
Although blood products are no longer a significant
mode of transmission in developed countries, many in-
dividuals with chronic infections today were infected by
this route. IVDU is the primary means of transmission
today and accounts for most new infections. Sexual
transmission appears to be uncommon. Little to no trans-
mission occurs between partners in a monogamous re-
lationship. Household transmission occurs at a low fre-
quency and is difficult to estimate. The spouse of an
infected individual only has a slightly higher risk than
other household members, and this increased risk could
be explained by other factors, such as sharing tooth-
brushes or razors. Household transmission probably re-
flects a lifetime likelihood of being exposed to contami-
nated blood. Maternal transmission occurs at a rate of
4–5% and is increased in mothers coinfected with HIV.
Community acquired HCV is a term used for individuals
with no known risk factor. Many of these individuals may
have used IV drugs at some time in their past but are notReceived October 5, 2001; returned to author for r
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willing to divulge this information.
The current therapy for HCV infection is interferon
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(IFN) in combination with ribavirin for 48 weeks. Combi-
nation therapy results in a 47% sustained viral clearance
rate. The combination of pegylated IFN with ribavirin has
recently been approved by the FDA and early indicators
suggest a higher response rate to this regime; 42 and
82% sustained viral clearance for genotype 1 and geno-
types 2/3, respectively (Manns et al., 2001). This therapy
is actually quite efficacious considering that individuals
are being treated after decades of chronic infection and
that both IFN and ribavirin are nonspecific antivirals. The
development of specific antivirals such as protease and
polymerase inhibitors is a major effort at most pharma-
ceutical companies, and clinical trials with these com-
pounds can be anticipated in the near future.
HCV: THE VIRUS
HCV is a member of the Flaviviridae family. The ge-
nome is single stranded RNA of positive sense (Fig. 1).
The 5 noncoding region contains an internal ribosome
entry site (IRES). The amino terminus of the viral polypro-
tein contains the structural proteins, the capsid and 2
envelope proteins, E1 and E2. The amino terminus of E2
has a 30-amino-acid hypervariable region that is nearly
100% divergent among different strains. Antibody re-
sponses to this region may result in the selection of
immune escape variants that are involved in persistence
of the virus. However, this sequence element is remark-
ably stable in chronically infected chimpanzees (Bassett
et al., 1999; Ray et al., 2000) and can be deleted from
infectious clones (Forns et al., 2000), and thus is not
essential for viability or viral persistence.
The function of p7 is not known. NS2/NS3 is a metal-
loprotease that cleaves NS2 from NS3. NS3 is a serine
protease that is responsible for all of the downstream
cleavages and is also the viral helicase. NS4A is a
cofactor for the serine protease, the function of NS4B is
unknown, and NS5A is discussed below. NS5B is the
viral polymerase. Most of the NS proteins are thought to
form the viral replicase, but other than NS3, NS4A, and
NS5B their precise functions are unknown. Following the
open reading frame (ORF) is a long 3 noncoding region
that has a variable region, a long poly(U)/polypyrimidine
stretch, the length of which appears to vary from one
strain to the next, and a highly conserved 98-nt terminus.
Of the viral proteins, NS5A has received the most
attention. NS5A is a phosphoprotein that contains a
sequence known as the interferon sensitivity determin-
ing region (ISDR). Enomoto et al. (1996) first demon-
FIG. 1. Schematic of HCV genome and replicon design. The HCV genome is depicted with the 5 noncoding region containing an internal ribosome
entry site (IRES) and the 3 noncoding region including a variable region (Var), a polyuridine–polypyrimidine stretch (U/PP), and a 98-nucleotide
conserved region (CR). The open reading frame of the polyprotein is depicted as a rectangle with demarcation of the individual viral protein domains
and the positions of some of the viral functions depicted above. The structure of the bicistronic replicon is illustrated below with the HCV IRES and
EMCV IRES regulating translation of the neomycin resistance gene and the nonstructural proteins of HCV, respectively. A T7 promoter is fused to the
HCV 5 terminus for the production of synthetic RNA. A domain of the NS5A protein is expanded to illustrate the ISDR, PKR binding domain, and the
adaptive replicon mutations.
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strated a relationship to sequence variation in this region
and resistance to IFN therapy. Gale and Katze have
shown that this region interacts with PKR, providing a
plausible mechanism for the modulation of the host re-
sponse to IFN (Gale et al., 1997, 1998). However, the
precise function of NS5A is still unknown, and whether
PKR binding accounts for viral resistance to IFN is still
controversial. The E2 envelope glycoprotein also inter-
acts with PKR, suggesting that the virus may have more
than one mechanism for modulating the host IFN re-
sponse (Taylor et al., 1999).
Over the past few years, there have been hundreds of
publications on the potential for the HCV proteins to
modulate host functions, but due to the limited nature of
this review, the details of these studies can not be dis-
cussed. The functions of the core protein (Choi et al.,
2001) and NS5A (Tan and Katze, 2001) have been re-
viewed recently as has the molecular biology of HCV
(Reed and Rice, 1998; Bartenschlager and Lohmann,
2000).
HCV REPLICONS
There have been two major breakthroughs with regard
to the development of systems for reverse genetics of the
virus. The first was the development of infectious cDNA
clones by Kolykhalov and co-workers (1997) followed
shortly by Yanagi and co-workers (1997). Both of these
clones were derived from the genotype 1a, H77 strain.
Several other infectious clones have been developed
since that time including two 1b clones (Yanagi et al.,
1998; Beard et al., 1999), a 2a clone (Yanagi et al., 1999)
and a clone of the prototype genotype 1a, HCV-1 strain
(Lanford et al., 2001c). Two major obstacles delayed the
production of these clones. In the absence of a tissue
culture system, the only test for infectivity was the direct
inoculation of synthetic RNA into the liver of a chimpan-
zee. In addition, due to either the variation present in the
quasispecies or errors introduced by PCR amplification,
construction of infectious cDNA clones required prepa-
ration of a consensus sequence from a number of
clones.
The next major development was the creation of a
culture system using a replicon constructed by Lohmann
and co-workers (1999). Figure 1 depicts the structure of
this bicistronic replicon. The 5 end of HCV including the
IRES and 12 codons of the core protein is fused in-frame
with the neomycin resistance gene, the EMCV IRES
drives translation of the HCV nonstructural proteins, and
the construct terminates with the 3 NCR of HCV. When
synthetic RNA from this construct is transfected into the
human liver cell line Huh7, G418-resistant colonies can
be isolated which persistently maintain the replicon
RNA. One unanticipated finding from this system is the
lack of a requirement for the NS2 protein in RNA repli-
cation.
The utility of this system was markedly enhanced
when Blight and co-workers (2000) demonstrated that
although colony forming efficiency was very low with the
original replicon, adaptive mutations arise that permit
highly efficient colony formation. This work has been
reproduced in several laboratories (Lohmann et al., 2001;
Krieger et al., 2001; Guo et al., 2001; Lanford et al., 2002).
The primary adaptive mutations are localized in a small
domain adjacent to the ISDR and PKR binding sites of
NS5A (Fig. 1), although adaptive mutations have been
observed in NS3, NS4B, and NS5B. One adaptive muta-
tion deletes the entire ISDR and much of the PKR binding
site, indicating that these functions are not required for
RNA replication or persistence in cell culture (Blight et
al., 2000). The mechanism by which these mutations
alter the colony forming ability of the replicon is not
currently known. However, the mutations do not confer
colony forming ability to genotype 1a replicons (Guo et
al., 2001; Blight et al., 2000; Lanford et al., 2002). Cur-
rently, the replicon model is limited to the original geno-
type 1b strain employed by Lohmann et al. (1999) and
one other genotype 1b isolate (Guo et al., 2001; Ikeda et
al., 2001), the HCV-N infectious clone sequence (Beard et
al., 1999). Replicons based on the HCV-N sequence do
not require adaptive mutations for high colony forming
efficiency. A four amino acid insertion in the ISDR ap-
pears to be responsible for the inherent colony forming
ability of this clone (Ikeda et al., 2001). In addition to
being restricted to two genotype 1b isolates, colony
formation with HCV replicons is limited to a single hu-
man liver cell line, Huh7. No one has reported success in
producing colonies with any other cell line. Persistence
of the replicon is very sensitive to IFN confirming that IFN
has a direct antiviral effect on the virus (Blight et al.,
2000; Frese et al., 2001; Guo et al., 2001; Lanford et al.,
2002).
Recognition of the adaptive mutations has permitted
extension of this system to full length clones. Inclusion of
the entire ORF into the bicistronic design permits selec-
tion of cells with stable expression of the entire polypro-
tein including the structural proteins (Peitschmann et al.,
2001; Ikeda et al., 2001), and construction of full length
genomes lacking foreign sequences but containing
adaptive mutations permits transient transfection assays
for authentic HCV RNA replication (Peitschmann et al.,
2001; C. Seeger, personal communication). At this time,
the secretion of infectious virions has not been demon-
strated for any of the full-length clones, but it is possible
that one of these systems will soon lead to a more
traditional tissue culture system for HCV.
THE CHIMPANZEE MODEL OF HCV
Currently, the only animal model for HCV infection is
the chimpanzee (reviewed in Lanford et al., 2001a). One
of the primary advantages of the chimpanzee is that it
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represents a truly unselected population. Most of what
we know of the clinical parameters of HCV infections in
humans is derived from cohorts that have been infected
for some period of time often decades. Very little infor-
mation is available with regard to the events that occur in
the first few months after infection. In contrast, chimpan-
zees are monitored from the time of exposure and all
exposed animals are characterized, thus the population
is unselected. Evaluation of the NANBH and HCV-ex-
posed chimpanzees in the colony at the Southwest Foun-
dation for Biomedical Research revealed that chimpan-
zees have a high viral clearance rate. Viral clearance
was documented in 61% of the animals with confirmed
infections (Bassett et al., 1998). This obviously repre-
sents a high rate of clearance compared to previous
estimates from human cohorts. Increased viral clearance
in chimpanzees can be explained if chimpanzees expe-
rience a different clinical course than humans, or if the
full clinical spectrum of HCV infections in humans has
not been observed because human cohorts are biased
for persistent infection. Recent data from several types of
human cohorts at least partially support a higher rate of
viral clearance in humans (Vogt et al., 1999; Wiese et al.,
2000; Koziel et al., 1997; Scognamiglio et al., 1999; Barrett
et al., 1999). The high rate of clearance in chimpanzees
makes it an ideal animal model for probing the mecha-
nism of clearance.
MICROARRAY ANALYSIS OF CHIMPANZEES
One of the techniques that we are currently using to
approach the mechanism of viral clearance is DNA mi-
croarray technology. This permits the characterization of
the entire profile of transcriptional changes occurring in
the liver of a chimpanzee at multiple time points during
acute resolving infection with HCV. At the onset of these
studies, four types of alterations in gene expression
were anticipated due to HCV infection: (i) changes in
expression due to interactions between the hepatocyte
and HCV proteins; (ii) changes due to the antiviral re-
sponse of the liver to the viral dsRNA which would
include type 1 IFNs and the IFN response genes; (iii)
changes due to the innate and adaptive immune re-
sponse to the infection, including activation and infiltra-
tion of NK cells, macrophages, and lymphocytes; and (iv)
changes due to the hepatocyte response to the cytokines
expressed by the immune cells.
The first animal analyzed using microarray technology
cleared viremia by week 8 postinfection, while viral RNA
in the liver was present for 14 weeks (Bigger et al., 2001).
This biphasic pattern of viral clearance from the circula-
tion and the liver suggests that there may be two mech-
anisms involved in viral clearance. The first reduced viral
replication to the point where viral RNA became unde-
tectable in the serum, and the second eliminated the
residual infected hepatocytes.
The DNA microarray data obtained from this animal
exhibited reproducibility across multiple time points and
showed that spurious alterations in gene expression
were low, since very few genes were altered 2 days after
infection (12 genes were increased and 2 genes were
decreased in expression). A progressive increase in the
number of genes with altered expression occurred until
the peak in alanine transaminase (ALT), at which time,
180 genes were altered by 3.5-fold or more. These in-
clude changes in metabolic genes, cell cycle regulation
genes, apoptotic markers, immune response genes and
most notably IFN response genes (Bigger et al., 2001).
Figure 2 illustrates the image from a scanned micro-
chip with enlargement of the region for one upregulated
gene (MK) and the kinetic patterns for some of the IFN
response genes with altered expression. A few genes
were up regulated by as much as 100-fold and many
were increased by 20-fold or more. Different genes ex-
hibited different kinetic patterns, but most returned to
near baseline levels by week 8 when viremia was
cleared. Increases were observed in IFN regulated tran-
scriptional factors (STAT1, STAT1, IFR7); IFN response
genes (p27, MxA, 2–5 OAS); and cytokine/chemokine
genes (ISG15, MK, IP-10). Some of the interferon re-
sponse genes are also double-stranded RNA response
genes, thus it is not clear whether some genes are being
induced due to the presence of viral RNA in infected cells
or due to the secretion of IFN by infected cells. The
repertoire of double-stranded RNA response genes was
recently delineated from IFN response genes using mi-
croarray analysis of cells lacking all type 1 IFN genes.
The results revealed that 175 genes were upregulated
and 95 genes were down regulated in response to dou-
ble-stranded RNA (Geiss et al., 2001).
Microarray analysis of viral clearance in chimpanzees
must be interpreted in context of the percentage of hepa-
tocytes infected. Peak viral RNA levels in the liver indi-
cated that no more than 10% of hepatocytes were in-
fected. The factors that limited infection to a subset of
hepatocytes may be the same factors involved in viral
clearance. A tentative model of viral clearance can by
hypothesized based on these data. A low percentage of
hepatocytes are infected initially. Double-stranded RNA
response genes are induced in infected cells, including
type 1 IFN genes, and secreted IFN induces an antiviral
state in neighboring uninfected cells. Such a scenario
would rapidly proceed to a loss of available replication
space within the liver as an increasing percentage of the
uninfected hepatocytes became exposed to IFN. The
spread of the infection would be limited and a decrease
in viremia would ensue. It is unlikely that this mechanism
alone would result in complete viral clearance in the
absence of an adaptive immune response. HCV specific
T cells presumably infiltrate the liver and eliminate the
residual infected hepatocytes by direct killing or by non-
cytolytic, cytokine-mediated elimination of viral RNA. Ob-
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viously considerable future work is needed to extend or
disprove this hypothesis. Although the role of IFN in viral
clearance has been controversial, a number of facts
attest to the potential importance of IFN in viral clear-
ance. The current regime of pegylated IFN with ribavirin
results in a high level of sustained viral clearance in the
treatment of chronic infections, recent studies have dem-
onstrated 98% viral clearance in treatment of acute HCV
infection with IFN (Jaeckel et al., 2001), and HCV repli-
cons are very sensitive to IFN. Nonetheless, the cumu-
lative host response is insufficient to eliminate the virus
in the majority of exposed individuals.
PROTECTIVE IMMUNITY IN CHIMPANZEES
Another aspect of the chimpanzee model that is expe-
riencing renewed interest is the protective immunity ob-
served following rechallenge of animals that previously
cleared infection. Previous studies observed little to no
protective immunity following rechallenge (Farci et al.,
1992; Prince et al., 1992), but more recent studies have
documented highly accelerated viral clearance and in
some cases sterilizing immunity upon rechallenge. Pro-
tective immunity was associated with a rapid memory T
cell proliferative response to HCV antigens (Bassett et
al., 2001) and rapid induction of IFN response genes
(C.B. and R.E.L., unpublished data). Rechallenge studies
provide an opportunity for a glimpse at the nature of the
protective immune response that may not be apparent
during primary infection, but becomes exaggerated with
a second exposure to HCV. Of 6 chimpanzees rechal-
lenged with a high dose inoculum, all animals exhibited
accelerated clearance, one of which was rechallenged
16 years after the primary infection (Bassett et al., 2001;
R.E.L., unpublished data). Two of the animals had steril-
izing immunity with no evidence of viremia, but nonethe-
less exhibited dramatic increases in IFN response genes
and IFN gamma expression (C.B. and R.E.L., unpublished
data). Most recently an animal rechallenged with a mix-
ture of four different genotypes cleared viremia within 2
weeks. These data have renewed confidence that a
protective vaccine for HCV is not only possible but prob-
able.
CORE TRANSGENIC MICE
The modulation of host functions by the core gene has
generated a great deal of interest. In cultured cells,
FIG. 2. Microarray analysis of alterations in host gene expression during HCV infection. The scanned image of an Affymetrix microarray chip is
illustrated. This microarray contains sequences from 6800 human genes (newer chips contain 12,000 genes). A single region of the chip representing
the MK gene has been expanded. The four grids represent the MK gene from four different arrays at four different times (day 0 and weeks 4, 6, and
14) during the acute infection of a chimpanzee with HCV. The grid is expanded to show the intensity of fluorescence for the 20 oligonucleotides used
to detect the MK transcript. The upper row of each grid represents the spots from oligonucleotides that match 20 sequences from the MK gene, while
the lower row on the grid represents the same oligonucleotides with a single mismatch to control for specificity of hybridization. An estimation of
change in gene expression is derived from a complex set of algorithms using the information from all 40 spots for each time point. The three graphs
depict the kinetic patterns of a series of IFN response genes altered in expression during acute resolving HCV infection. Viremia was cleared prior
to week 8, thus the rapid return to baseline for many of these transcripts.
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expression of core protein from heterologous promoters
results in a myriad of effects including transcriptional
regulation of a number of genes, enhancement or inhi-
bition of apoptosis, association with lipid droplets and
apolipoproteins, and perturbation of lipid metabolism
(Choi et al., 2001). Core protein also binds to the cyto-
plasmic tail of lymphotoxin- receptor and to the death
domain of tumor necrosis factor receptor 1 (Matsumoto
et al., 1997; Zhu et al., 1998).
Studies using transgenic mice that express the core
protein have been the most revealing of the potential
effects of the core protein on host metabolism. Although
no immediate pathology from the expression of core is
apparent in most core transgenic systems, in one trans-
genic line, a lymphocytic infiltrate with hepatocyte necro-
sis is observed in conjunction with an enhanced sensi-
tivity to anti-Fas antibody (Honda et al., 1999). Perhaps
the most significant phenotype observed in core trans-
genic mice is the induction of steatosis and hepatocel-
lular carcinoma (HCC), both of which are hallmarks of
chronic HCV infections (Moriya et al., 1997, 1998; Lerat et
al., 2001). Increased lipid peroxidation and mitochondrial
DNA damage, both indicators of increased reactive ox-
ygen species (ROS), have been noted in some core
transgenic mice (Moriya et al., 2001). The authors sug-
gest that development of HCC in core transgenic mice
and potentially HCV-infected individuals may be attribut-
able to the generation of ROS in the liver and subsequent
DNA damage. Studies in cultured cells have confirmed a
role for core protein in induction of oxidative stress,
potentially through a direct interaction with mitochondria
(Okuda et al., 2001).
Steatosis and HCC have been observed in two other
transgenic lines, one expressing the structural proteins
(core/E1/E2/p7) and the other containing the entire HCV
ORF (Lerat et al., 2001). Although protein expression is
below the limits of detection in mice containing the entire
ORF, these mice exhibit the highest level of HCC, sug-
gesting that nonstructural proteins may also play a role
in HCC. Neither of these lines exhibit elevated lipid
peroxides under basal conditions (Lerat et al., 2001), but
increased lipid peroxidation is observed in the mice
expressing the structural region following treatment with
carbon tetrachloride (Okuda et al., 2001). It should be
noted that not all lines of core transgenic mice develop
steatosis and HCC. Whether these differences are due to
the transgene constructs, the particular transgenic lines,
or the different strains of mice employed is not clear at
this time.
Of potential importance when evaluating the functions
of the core gene is the recent observation that an addi-
tional protein can be encoded from this region by ribo-
somal frameshift (Xu et al., 2001). The product of the
frameshift has been designated F protein and contains
the first 10 codons of the core gene and has a length of
126–162 amino acids depending on the HCV genotype.
Although an antibody response to this protein has been
confirmed in HCV-infected patients, at this time, no func-
tion has been determined.
MICE WITH HUMAN LIVERS
Mice that over express a urokinase plasminogen ac-
tivator (uPA) transgene from the albumin promoter expe-
rience hepatocellular atrophy beginning at birth when
the albumin promoter becomes active (Sandgren et al.,
1991). Animals heterozygous for this transgene sponta-
neously loose the transgene at a low frequency, and the
normal hepatocytes then repopulate the liver. Homozy-
gous animals can be rescued by transplantation of nor-
mal hepatocytes which undergo rapid proliferation to
replace dying hepatocytes. This system documented the
near unlimited proliferation potential of adult hepato-
cytes by transplantation of genetically marked hepato-
cytes (Rhim et al., 1994). The model has been exploited to
introduce xenotransplants of hepatocytes from species
susceptible to hepatitis viruses into double transgenic
mice that are immunodeficient. This was first accom-
plished with woodchuck hepatocytes infected with
woodchuck hepatitis B virus (Petersen et al., 1998) and
more recently with human hepatocytes that could be
infected with hepatitis B virus (Dandri et al., 2001) and
HCV (Mercer et al., 2001). Transplanted human hepato-
cytes form proliferative nodules throughout the mouse
liver that can be infected with HCV by inoculation of the
mice with human serum. Most importantly, the hepato-
cytes survive for up to 35 weeks, the mice experience
high levels of viremia, and the virus can be serially
passed to new mice. This system may find its greatest
utility in the evaluation of the antivirals currently being
developed by pharmaceutical companies. Furthermore,
the passive transfer of antibodies from immunized mice
may permit assays for neutralizing antibodies, and adop-
tive transfer with human T cells and bone marrow may
also be possible. Certainly, the model will provide inter-
esting observations in the future.
GBV-B, A SURROGATE MODEL FOR HCV
Of the various viruses employed as surrogates for
HCV, GBV- B represents one of the best suited (reviewed
in Beames et al., 2001). It is the virus most closely related
to HCV and like HCV, it is hepatotropic. In addition,
GBV-B overcomes several limitations that are problem-
atic with HCV research. The level of viremia observed in
infected tamarins, the animal model for GBV-B, is greater
than 1000-fold higher than for HCV, tamarins weigh 100-
fold less than a chimpanzee, and a robust tissue culture
system for GBV-B has been developed using primary
tamarin hepatocytes (Beames et al., 2000; Lanford et al.,
2001b).
Historically, the original GB inoculum was obtained
from a surgeon with the initials GB who contracted hep-
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atitis. Dienhardt et al. (1967) inoculated tamarins with this
serum and one of the animals developed hepatitis. At the
time, it was assumed that the hepatitis agent came from
the surgeon; however, in retrospect it seems likely that
the agent was already present in the tamarin and that
GBV-B represents a tamarin virus. GBV-B and a closely
related nonhepatotropic virus designated GBV-A were
later cloned from a passage of the original tamarin se-
rum (Simons et al., 1995). Recently, infectious clones of
GBV-B have been constructed that induce hepatitis in
tamarins (Bukh et al., 1999; Martin et al., 2002).
Previous studies suggest that all GBV-B infections are
acute resolving infections; however, recently chronic in-
fections have been obtained by two different ap-
proaches. Transient immunosuppression with FK506 re-
sulted in a very high level viremia for 46 weeks, 16 weeks
after discontinuation of immunosuppression (R.E.L., un-
published data). In addition, one animal inoculated with
RNA from an infectious clone remains persistently in-
fected 52 weeks after inoculation without the use of
immunosuppression (Martin et al., 2002). Whether this is
a particular aspect of this clone, or infections induced
with synthetic RNA, or whether chronic infections with
GBV-B occur at a low but previously unrecognized fre-
quency remains to be determined. One attribute of re-
solving GBV-B infections that warrants more attention is
the nature of viral clearance. Since the serum ALT values
often peak and decline before any drop in the level of
viremia, a noncytolytic mechanism of clearance presum-
ably plays an important role. It is also noteworthy that
viral clearance following immunosuppression occurs in
the absence of a significant rise in ALT.
Our major emphasis with GBV-B has been on the
creation of a tissue culture system that would permit
studies that have been difficult or impossible to conduct
with HCV. To this end, we developed a tissue culture
system based on primary tamarin hepatocyte cultures. In
vitro infection using this system is efficient with secreted
viral levels of greater than 107 particles per milliliter of
culture medium being attained by 3 days after infection
(Beames et al., 2000). Viral antigens are easily detected
by immunofluorescence, something that has been prob-
lematic in HCV with the exception of antigen in replicon
cell lines. This culture system has been utilized to eval-
uate antivirals with poly(IC) and ribavirin both inducing a
3-log decrease in the level of viral RNA.
Further studies demonstrated that the mechanism of
action for ribavirin in this system was induction of error
prone replication, presumably due to the incorporation of
ribavirin triphosphate by the GBV-B polymerase. This
hypothesis was examined by demonstrating that virus
produced in the presence of ribavirin had a markedly
reduced specific infectivity upon passage to fresh cul-
tures. In fact, virus grown in the presence of ribavirin for
6 days was essentially noninfectious (Lanford et al.,
2001b). Similar observations have been made recently
using the poliovirus model (Crotty et al., 2001) and using
the HCV replicon system (Lanford et al., 2002). These
findings prompted speculation on the mechanism by
which ribavirin enhances the rate of sustained viral
clearance in HCV-infected individuals treated with IFN.
The improvement in liver disease realized during ribavi-
rin monotherapy can not be attributed to error prone
replication, since ribavirin monotherapy does not result
in a significant reduction in viral load. Although it is likely
that the immunomodulatory properties of ribavirin are
involved in both the improvement of liver disease during
monotherapy and the increased rate of sustained viral
clearance observed with IFN/ribavirin combination
therapy, the possibility that this synergism is due in part
to ribavirin-induced error prone replication can not be
dismissed. The small increase in error rate that may
occur at the levels of ribavirin used in the clinic may
result in too few lethal mutations to impact the replica-
tion pool of viral RNA. In contrast, this error rate may
have a significant impact, once IFN has reduced the viral
load to an extent that it is undetectable by RT-PCR, and
thus lead to a higher rate of sustained viral clearance.
The GBV-B tissue culture model should find great
utility in the evaluation of antivirals produced for HCV,
development of neutralization assays to evaluate vaccine
strategies, and exploration of host–viral interactions in-
cluding viral receptors.
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